MX2010001733A - Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis. - Google Patents

Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis.

Info

Publication number
MX2010001733A
MX2010001733A MX2010001733A MX2010001733A MX2010001733A MX 2010001733 A MX2010001733 A MX 2010001733A MX 2010001733 A MX2010001733 A MX 2010001733A MX 2010001733 A MX2010001733 A MX 2010001733A MX 2010001733 A MX2010001733 A MX 2010001733A
Authority
MX
Mexico
Prior art keywords
compounds
imidazopyrazine compounds
formula
imidazopyrazine
cvb
Prior art date
Application number
MX2010001733A
Other languages
English (en)
Inventor
Clifford John Harris
Dale Robert Mitchell
Angus Macleod
Nicholas John Palmer
Michael Daniel Goldsmith
Christophe Claude Parsy
Original Assignee
Biofocus Dpi Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofocus Dpi Ltd filed Critical Biofocus Dpi Ltd
Publication of MX2010001733A publication Critical patent/MX2010001733A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Abstract

La presente invención se refiere a nuevos compuestos de imidazopirazina que tienen una fórmula representada por la siguiente fórmula (l) Los compuestos pueden ser preparados como composiciones farmacéuticas, y pueden ser utilizados para la prevención y el tratamiento de una infección viral, en particular una infección por VHC, HRV, Sb, y/o CVB en un paciente que tenga la necesidad del mismo.
MX2010001733A 2007-08-21 2008-08-20 Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis. MX2010001733A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0716292.8A GB0716292D0 (en) 2007-08-21 2007-08-21 Imidazopyrazine compounds
PCT/EP2008/060896 WO2009024585A2 (en) 2007-08-21 2008-08-20 Imidazo [1,2-a] pyrazine compounds for treatment of viral infections such as hepatitis

Publications (1)

Publication Number Publication Date
MX2010001733A true MX2010001733A (es) 2010-07-06

Family

ID=38566736

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001733A MX2010001733A (es) 2007-08-21 2008-08-20 Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis.

Country Status (21)

Country Link
US (1) US8362018B2 (es)
EP (2) EP2567960A3 (es)
JP (1) JP2010536825A (es)
KR (1) KR20100081294A (es)
CN (1) CN101835780B (es)
AU (1) AU2008290531A1 (es)
BR (1) BRPI0815717A2 (es)
CA (1) CA2707521A1 (es)
CY (1) CY1113872T1 (es)
DK (1) DK2193131T3 (es)
ES (1) ES2404415T3 (es)
GB (1) GB0716292D0 (es)
HK (1) HK1143810A1 (es)
HR (1) HRP20130202T1 (es)
MX (1) MX2010001733A (es)
NZ (1) NZ584108A (es)
PL (1) PL2193131T3 (es)
PT (1) PT2193131E (es)
SI (1) SI2193131T1 (es)
WO (1) WO2009024585A2 (es)
ZA (1) ZA201002009B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0716292D0 (en) * 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009134666A1 (en) 2008-04-29 2009-11-05 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
JP5411927B2 (ja) 2008-05-06 2014-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１アンタゴニストとしてのピラゾール化合物
UA103634C2 (en) 2008-09-26 2013-11-11 Берингер Ингельхайм Интернациональ Гмбх Azaindazole compounds as ccr1 receptor antagonists
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
IN2012DN03449A (es) 2009-10-21 2015-10-23 Boehringer Ingelheim Int
JP5542214B2 (ja) 2009-10-27 2014-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体アンタゴニストとしての複素環化合物
MX2012004990A (es) 2009-10-30 2012-06-12 Janssen Pharmaceutica Nv Deribados de imidazo [1,2-b] pirimideazina y su uso como inhibidores de la enzima fosfodiesterasa 10.
BR112012013582A2 (pt) * 2009-12-08 2016-07-05 Boehringer Ingelheim Int processo para síntese de intermediários úteis para a produção de compostos de indazol e azaindazol substituídos
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
ES2551407T3 (es) * 2010-03-18 2015-11-18 Bayer Intellectual Property Gmbh Imidazopirazinas
US8871786B2 (en) 2010-04-30 2014-10-28 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as CCR1 receptor antagonists
ES2555261T3 (es) 2010-06-01 2015-12-30 Bayer Intellectual Property Gmbh Imidazopirazinas sustituidas
EP2651945A1 (en) * 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012080232A1 (en) * 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
JP5824065B2 (ja) * 2010-12-17 2015-11-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン
EP2651950A1 (en) 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US20130303532A1 (en) * 2010-12-17 2013-11-14 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
WO2012080228A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
EP2655371B1 (en) 2010-12-23 2015-02-25 Boehringer Ingelheim International GmbH Pyrazolopiperidine compounds as ccr1 receptor antagonists
GB201109763D0 (en) * 2011-06-10 2011-07-27 Ucl Business Plc Compounds
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
EP2772485A4 (en) * 2011-10-24 2015-06-10 Takeda Pharmaceutical BICYCLIC CONNECTION
CN104411312B (zh) 2012-06-26 2018-03-06 詹森药业有限公司 包括pde2抑制剂例如1‑芳基‑4‑甲基‑[1,2,4]***[4,3‑a]‑喹喔啉化合物和pde10抑制剂的用于在治疗神经病学障碍或代谢障碍中使用的组合
MX362197B (es) 2012-07-09 2019-01-08 Janssen Pharmaceutica Nv Derivados de imidazo[1,2-b]piridazina e imidazo[1,2-a]pirazina como inhibidores de la fosfodiesterasa 10; y el uso de los mismos en el tratamiento de trastornos neurológicos, psiquiátricos y metabólicos.
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
AU2016255431B2 (en) * 2015-04-29 2020-05-07 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators
CN107835814B (zh) 2015-04-29 2021-07-23 詹森药业有限公司 氮杂苯并咪唑及其作为ampa受体调节剂的用途
BR112017026061B1 (pt) * 2015-06-24 2023-03-28 Curovir Ab Composto, composição farmacêutica, e, uso de um composto
JP6507976B2 (ja) * 2015-09-30 2019-05-08 東レ株式会社 イミダゾール−２−カルボン酸エステル誘導体又はその塩の製造方法
MA43169B1 (fr) 2015-11-06 2022-05-31 Incyte Corp Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
WO2017120194A1 (en) 2016-01-05 2017-07-13 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
PL3436074T3 (pl) * 2016-03-31 2020-11-02 Romark Laboratories, L.C. Związki z grupą tiazolidynową do leczenia zakażeń wirusowych
AR108875A1 (es) 2016-06-24 2018-10-03 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
TW201817714A (zh) 2016-08-30 2018-05-16 英商葛蘭素史密斯克藍智慧財產權有限公司 抑制3c及3cl蛋白酶之化合物及其使用方法
LT3697789T (lt) 2017-10-18 2021-12-10 Incyte Corporation Kondensuoti imidazolo dariniai, pakeisti tretinėmis hidroksigrupėmis, kaip pi3k-gama inhibitoriai
UY38051A (es) 2018-01-17 2019-08-30 Glaxosmithkline Ip Dev Ltd INHIBIDORES DE LA PI4KIIIß
CN112752761B (zh) 2018-08-21 2024-03-29 杏林制药株式会社 双环杂芳族环衍生物
MA53561A (fr) 2018-09-05 2022-05-11 Incyte Corp Formes cristallines d'un inhibiteur de phosphoinositide 3-kinase (pi3k)
CN109369545B (zh) * 2018-12-14 2020-04-10 东营曜康医药科技有限公司 2-甲基-5-甲酸吡嗪的合成工艺
US20230014730A1 (en) 2019-09-23 2023-01-19 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
CN115667264A (zh) * 2020-06-08 2023-01-31 豪夫迈·罗氏有限公司 新型咪唑并-吡嗪衍生物
CN113929633A (zh) * 2021-10-27 2022-01-14 山东大学 一种法匹拉韦的合成方法及其应用
CN113831255B (zh) * 2021-11-25 2022-03-11 山东诚创蓝海医药科技有限公司 一种2-氨基丙二酰胺的制备方法
CN115489188B (zh) * 2022-10-09 2023-08-29 安徽国风新材料股份有限公司 一种家居保护用聚酯薄膜及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607813B1 (fr) * 1986-12-05 1989-03-31 Montpellier I Universite Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique
DE19915178A1 (de) 1999-04-03 2000-10-05 Univ Mainz Johannes Gutenberg Hepatitis C Virus Zellkultursystem
IL152671A0 (en) 2000-05-23 2003-06-24 Univ Washington Hcv variants
AU2002225895A1 (en) 2000-11-07 2002-05-21 Anadys Pharmaceuticals, Inc. Hepatitis c virus constructs characterized by high efficiency replication
DE60128835T2 (de) 2000-12-22 2008-03-20 Boehringer Ingelheim (Canada) Ltd., Laval Selbstreplizierendes rna-molekül aus hepatitis-c-virus
WO2002059321A2 (en) 2001-01-23 2002-08-01 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Hepatitis c virus replicons and replicon enhanced cells
US20040102455A1 (en) * 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
EP1543008B1 (en) 2002-09-23 2007-11-07 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
AU2007200401A1 (en) * 2002-09-23 2007-02-22 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
US7807455B2 (en) 2003-02-13 2010-10-05 Merck Sharp & Dohme Corp. Method to confer cell culture replication activity to different Hepatitis C virus isolates
AR043002A1 (es) 2003-02-18 2005-07-13 Altana Pharma Ag Imidazopirazinas 6-substituidos
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7186832B2 (en) * 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US20070105864A1 (en) * 2005-11-10 2007-05-10 Schering Corporation Methods for inhibiting protein kinases
EP1945644A2 (en) 2005-11-10 2008-07-23 Schering Corporation Imidazopyrazines as protein kinase inhibitors
US8268809B2 (en) * 2006-09-05 2012-09-18 Emory University Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
US20100144743A1 (en) 2006-09-05 2010-06-10 Board Of Regents, The University Of Texas System Compositions and methods for inhibition of tyrosine kinases
MX2009005011A (es) 2006-11-08 2009-05-20 Schering Corp Imidazopirazinas como inhibidores de proteina quinasa.
WO2008059373A1 (es) 2006-11-17 2008-05-22 Raqualia Pharma Inc. Vacuna contra la malaria, basada en la subunidad 200l de la proteína msp1 de plasmodium vivax.
US8243049B2 (en) 2006-12-20 2012-08-14 3M Innovative Properties Company Untethered stylus employing low current power converter
GB0716292D0 (en) * 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds

Also Published As

Publication number Publication date
WO2009024585A2 (en) 2009-02-26
HRP20130202T1 (hr) 2013-04-30
PT2193131E (pt) 2013-04-04
NZ584108A (en) 2012-06-29
CN101835780B (zh) 2013-09-18
EP2193131A2 (en) 2010-06-09
US20110166147A1 (en) 2011-07-07
EP2567960A2 (en) 2013-03-13
ZA201002009B (en) 2010-12-29
DK2193131T3 (da) 2013-04-22
SI2193131T1 (sl) 2013-06-28
EP2193131B1 (en) 2013-01-30
BRPI0815717A2 (pt) 2015-02-10
JP2010536825A (ja) 2010-12-02
HK1143810A1 (en) 2011-01-14
US8362018B2 (en) 2013-01-29
CA2707521A1 (en) 2009-02-26
EP2567960A3 (en) 2013-06-05
KR20100081294A (ko) 2010-07-14
CN101835780A (zh) 2010-09-15
GB0716292D0 (en) 2007-09-26
AU2008290531A1 (en) 2009-02-26
ES2404415T3 (es) 2013-05-27
PL2193131T3 (pl) 2013-07-31
CY1113872T1 (el) 2016-07-27
WO2009024585A3 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
MX2010001733A (es) Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis.
TN2012000416A1 (en) Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
WO2008127364A3 (en) Antiviral compounds and use thereof
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
WO2012018534A3 (en) Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
SG178952A1 (en) Chemical compounds
IL182315A0 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
HK1145839A1 (en) N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
NZ585226A (en) Inhibitors of human immunodeficiency virus replication
WO2010084115A3 (en) Antiviral agents
ZA200900935B (en) Hepatitis C virus inhibitors
TN2012000264A1 (en) Hepatitis c virus inhibitors
TN2012000214A1 (en) Hepatitis c virus inhibitors
WO2008021936A3 (en) Hepatitis c virus inhibitors
TN2010000137A1 (en) Spiropyrrolidines and their use against hcv and hiv infection
MY152971A (en) Hepatitis c virus inhibitors
MX2010009563A (es) Compuestos quimicos con accion antiviral contra virus de dengue y otros flavivirus.
MX2012007076A (es) Terapia combinada de hcv.
WO2007041632A3 (en) Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
TN2015000293A1 (en) Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
MX2011011618A (es) Agentes terapeuticos 713.
TW200800993A (en) Organic compounds

Legal Events

Date Code Title Description
FG Grant or registration